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problem. Cases of early-stage CKD are now reaching epidemic
proportions. Only recently has CKD become a major priority of
care for the health system. The decline in renal function in
CKD is mediated by arterial hypertension, glomerular capil-
lary hypertension and hyperﬁlatration, oxidative stress,
inﬂammation, and lipid disorders. CKD itself results in pro-
found alterations in lipid metabolism and plasma lipid pro-
ﬁles characterized by hypertriglyceridemia, diminished HDL
cholesterol, impaired HDL maturation, and depressed HDL
antioxidant and anti-inﬂammatory activities [1–3]. The asso-
ciated dyslipidemia has been shown to contribute to aggrava-
tion of CKD and cardiovascular disease (CVD) in patients with
CKD, and lipid-lowering therapies have proven effective in
ameliorating progression of renal disease and CVD [4,5].
Cellular lipid accumulation in the kidney has been shown to
promote or accelerate kidney disease in animal models of CKD
(5/6 nephrecomized rats) [6].
CKD is known to be associated with accelerated arterio-
sclerosis and atherosclerosis. Importantly, CVD is the main cause
of morbidity and mortality in patients with CKD. A recent study
suggested the potential beneﬁt of lipid-lowering mediation
in preventing cardiovascular events in patients with CKD [7].
Abnormalities in calcium–phosphorus homeostasis, including
signiﬁcant elevations in serum phosphorus concentrations, are
thought to contribute to arterial stiffening, hypertension, and
CVD risk in patients with CKD [8–11]. Even serum phosphorus
concentrations within the normative range are linearly asso-
ciated with subclinical arteriosclerosis and the development of
incident CVD [11]. Therefore, phosphorus-lowering drugs that
simultaneously target other cardiovascular risk factors in
CKD, for example, dyslipidemia, might have additive or synergic
beneﬁts.
In this issue of Kidney Research and Clinical Practice, Kang
et al [11] evaluated whether low-dose niacin supplementa-
tion (500 mg/d for 6 months) can improve dyslipidemia and
lower serum phosphorus. They also examined the frequencies
of adverse effects in CKD patients (i.e., Stages 2–4) receiving
low-dose niacin treatment. By retrospectively comparing the
effects of dyslipidemia and serum phosphorus in 31 patients
receiving niacin treatment to 30 CKD control patients who did
not receive niacin treatment, they found that niacin treatment
increased HDL cholesterol and decreased triglycerides and132/$ - see front matter & 2013. The Korean Society of Nephrology. P
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dx.doi.org/10.1016/j.krcp.2013.02.001serum phosphorus. In addition, niacin treatment improved
the glomerular ﬁltration rate compared to baseline values.
There were few adverse effects, and only 8% of CKD patients
discontinued niacin treatment. They concluded that low-dose
niacin improves dyslipidemia, lows serum phosphorus, and
increases GFR in patients with CKD with a low frequency of
adverse effects. The authors recommended that low-dose
niacin is efﬁcient and very well tolerated, which makes it
ideal for the treatment of CKD patients with hyperlipidemia
and hyperphosphatemia.
Niacin (nicotinic acid, vitamin B3) is a water-soluble
vitamin that is critical for cellular metabolism [12]. As a
broad-spectrum drug that can affect lipid levels, niacin
inhibits adipocyte lipolysis via nicotinic acid receptors, low-
ering total cholesterol, triglyceride, LDL cholesterol, and VLDL
cholesterol, and also increasing HDL cholesterol at a dose of
1–3 g/d [13–15]. Niacin also lowers serum phosphorus levels
in patients with CKD, as it is also a direct inhibitor of
phosphate absorption from the GI tract [15,16]. It is recently
become well known that nicotinamide inhibits the Na Pi-2b
and Na Pi-2a sodium-dependent phosphate cotransporters of
the GI tract [17] and kidneys [18], respectively. Furthermore,
niacin plays a key role in cardiovascular diseases and
cardiovascular-related mortality by modifying both dyslipi-
demia and phosphorus levels [19]. Interestingly, Kang et al
also demonstrated in their study that low-dose niacin treat-
ment improved renal function in their study, which is only
associated with niacin treatment. A recent study showed that
niacin administration improves renal tissue lipid metabolism,
renal function and structure, hypertension, proteinuria, and
histological tubulointerstitial injury in an animal model of 5/6
nephrecomized rats [6]. The authors concluded that niacin
supplementation mitigates the upregulation of oxidative
stress and the inﬂammatory system in the kidney. However,
in another study, niacin treatment (1 g/d for 4 weeks and
advanced to 2 g/d for 20 weeks) in patients with CKD (i.e., Stages
2–3) did not show renoprotective effects [20]. Despite these
positive roles of niacin, physicians hesitate to prescribe niacin
because of its various adverse effects, such as prostaglandin-
mediated hot ﬂushing, liver function test disruption, exacerba-
tion of peptic ulcer disease, nausea, vomiting, pruritus, hives,
constipation, increased uric acid levels, and thrombocytopenia.
Some of these adverse effects are slight and easily controlled byublished by Elsevier. This is an open access article under the CC BY-NC-
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necessitate cessation of niacin administration [14,15]. The
metabolism of niacin and nicotinamide in subjects with CKD
has not yet been studied, so the appropriate dosing in such
patients is unknown. Approximately 75 % of a dose of niacin is
excreted in the urine as the parent drug and several metabolites
(mainly the latter) in normal subjects, regardless of the type of
the niacin preparation [19]. However, there is no published
information available on the pharmacokinetics of niacin in
patients with advanced CKD or end-stage renal disease. There-
fore, before niacin can be used safely, niacin’s side effects
(chieﬂy facial ﬂushing) must be minimized and the pharmaco-
kinetics of niacin in patients with CKD or end-stage renal
disease must be clariﬁed.
In conclusion, recent experimental and clinical studies,
including that of Kang et al [11], suggest that niacin and its
metabolites nicontinamide could be used to treat hyperlipi-
demia and to lower phosphate levels in patients with CKD.
However, further studies are needed to evaluate whether
long-term treatment with low-dose niacin is effective, well
tolerated, and safe and has a preventive effect on the progres-
sion of CKD.Conﬂicts of interest
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